Stockreport

Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations [Yahoo! Finance]

Aytu BioPharma, Inc.  (AYTU) 
NASDAQ:AMEX Investor Relations: aytubio.com/investors/stock-information
PDF Key Financial Results Revenue: US$81.0m (down 25% from FY 2023). Net loss: US$15.8m (loss narrowed by 7.1% from FY 2023). US$2.86 loss per share (improved from US [Read more]